Akums Drugs and Pharmaceuticals Ltd (AKUMS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated August 05, 2026 3 min read

Akums Drugs and Pharmaceuticals operates as a major CDMO player, balancing robust volume growth in its core business against the challenges of a volatile API market and recent manufacturing disruptions. Investors will be watching for updates on the sustainability of recent volume gains, the impact of the Haridwar site recovery, and progress on international contract ramp-ups.

Quick Details

Results date	August 08, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 1,158 Cr
Previous quarter PAT	Rs. 81 Cr
Previous quarter EBITDA margin	13.1%
Market cap	Rs. 10,483.22 Cr
CMP	Rs. 666.1

Akums Drugs and Pharmaceuticals Ltd Q1 Results Date and Time

The board meeting is scheduled for August 08, 2026, to consider the audited financial results and recommend dividend for FY2026.

What to expect from Akums Drugs and Pharmaceuticals Ltd's Q1 FY27 results

Akums enters Q1 FY27 with a strong CDMO foundation, having sustained >25% volume growth in the final two quarters of FY26. While the early-quarter API price surge likely pressured margins, the company's cost-plus model provides a buffer, and the June softening of prices offers a potential exit-rate tailwind. Management's guidance for an effective tax rate of ~29% for FY27, down from 32% in FY26, may begin to provide support to the bottom line this quarter. The company continues to navigate a persistent ~Rs. 19 Cr quarterly notional interest charge related to its EU contract, which will remain until commercial supplies commence in FY28. Operational focus remains on the ramp-up of the new injectable facility, which was at low-teens utilization in Q4 FY26, and the recovery of the Rs. 20 Cr in supplies delayed by the May Haridwar labour disruption.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress on key strategic and operational targets.

Capex of Rs. 300 Cr in FY27: track actual vs target
Zambia supplies of $25M from India: confirm if first shipments occurred in Q1
API business turnaround: any sequential EBITDA improvement from the FY26 loss of Rs. 40 Cr
Injectable facility ramp-up: update on utilization rates
Effective tax rate: confirm if the target of ~29% is visible

Strategic execution and M&A: Status updates on recent inorganic growth and international expansion.

Oriflame manufacturing business acquisition: update on integration plans ahead of the August 31, 2026 completion target
EU dossier filings: progress on country-level registrations for products like rivaroxaban
Zambia facility construction: progress toward the H2 FY28 operational timeline

Risks and headwinds to monitor: Management-flagged risks impacting short-term operations.

Haridwar labour disruption: confirmation that the Rs. 20 Cr production loss was fully recovered within Q1
Income Tax appeals: status of the aggregate Rs. 156 Cr demand across parent and subsidiary entities
API price volatility: assessing the impact of the early-quarter price spike on CDMO margins

Frequently Asked Questions

What was the impact of the Haridwar manufacturing site disruption?

The May 2026 labour unrest caused a 4-day partial disruption, resulting in a delayed supply of approximately Rs. 20 Cr. Management reported that operations resumed at 100% capacity on May 18 and expected to recover the production loss in subsequent weeks.

Is the API business showing signs of a turnaround?

The API segment remained loss-making in FY26 with an EBITDA of -Rs. 40 Cr. Management is working toward breakeven but has not provided a specific timeline for when the business will become month-on-month profitable.

How is the company managing its CDMO margin profile?

CDMO margins are supported by a cost-plus model that adjusts over 2-3 year cycles, helping to mitigate short-term API price volatility. Management expects margins to remain in the current range, driven by operating leverage from high volume growth and a shift toward higher-margin export contracts.